Dr. Vanderslice has spent over 20 years leading teams focused on the development of small molecule compounds that bind and modulate the function of integrins and chemokine receptors. The majority of his professional career has been in the pharmaceutical industry, where he gained familiarity with each stage of the pipeline from discovery to progression into clinical trials. Dr. Vanderslice has led teams working on several pre-clinical programs involving efforts in drug screening, lead compound characterization, and the development of preclinical animal models.See Publications
Texas Heart Institute Positions
- Senior Investigator and Director, MCRL, Molecular Cardiology Research
- Non-invasive diagnostic imaging technologies
University of Maryland
University of Texas at Austin (PhD)
University of California San Francisco
Honors, Awards and Memberships
- Parker B. Francis Fellowship in Pulmonary Research, University of California, San Francisco, CA
- Texas Heart Institute Professional Staff
Houston, TX, May 20, 2022 – Together with The University of Texas MD Anderson Cancer Center (“MD Anderson”) and Texas...
Texas Heart Institute (THI) Molecular Cardiology researchers Peter Vanderslice, PhD, and Ronald J. Biediger, PhD, were recently awarded a grant from...
The impact of a scientific article is often described in terms of how many times the article has been cited...